PRLD
Prelude Therapeutics Incorporated$4.35-0.17 (-3.76%)Prev Close$4.52·MCap$170.5M·P/E—·Vol155.7K·Yield—
▲
Buys (12M)
3
$25.00M
▼
Sells (12M)
2
$7.6K
◆
Net Activity
Net Buyer
$24.99M
●
Active Insiders
4
last 12 mo
Over the past 12 months, insider activity at Prelude Therapeutics Incorporated (PRLD) has been dominated by buying, with 3 insider purchases totaling $25.00M and 2 insider sales totaling $7.6K. The most recent insider transaction was by Bonita David P (director, 10 percent owner: ), who purchased $12.50M worth of shares on Apr 23, 2026. Prelude Therapeutics Incorporated operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $170.5M.
PRLD Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 23, 2026 | Bonita David P | director, 10 percent owner: | Buy | 2,815,315 | $4.44 | $12.50M3.7% OS | 11,808,945+31% |
| Apr 23, 2026 | ORBIMED ADVISORS LLC | director, 10 percent owner: | Buy | 2,815,315 | $4.44 | $12.50M3.7% OS | 11,808,945+31% |
| Apr 22, 2026 | BAKER BROS. ADVISORS LP | director, 10 percent owner: | Buy | 2,252,252 | $0.00 | $225.232.9% OS | 20,105,994 |
| Oct 4, 2025 | Huang Jane | President, CMO | Sell | 3,355 | $1.47 | $4.9K | 0 |
| Jul 4, 2025 | Huang Jane | President, CMO | Sell | 3,355 | $0.79 | $2.7K | 0 |
| Apr 4, 2025 | Huang Jane | President, CMO | Sell | 3,355 | $0.68 | $2.3K | 0 |
| Mar 25, 2025 | Combs Andrew | Chief Chemistry Officer | Buy | 100,000 | $0.69 | $69.3K | 0 |
| Mar 25, 2025 | Vaddi Krishna | CEO | Buy | 675,000 | $0.69 | $467.4K0.9% OS | 0 |
| Mar 20, 2025 | Vaddi Krishna | CEO | Buy | 20,416 | $0.73 | $14.9K | 0 |
| Mar 14, 2025 | Vaddi Krishna | CEO | Buy | 39,105 | $0.75 | $29.5K | 0 |
| Mar 12, 2025 | Vaddi Krishna | CEO | Buy | 97,500 | $0.71 | $69.6K | 0 |
| Jan 3, 2025 | Vaddi Krishna | CEO | Buy | 5,000 | $1.21 | $6.0K | 142,553 |
| Jan 2, 2025 | Vaddi Krishna | CEO | Buy | 10,000 | $1.20 | $12.0K | 137,553 |
| Dec 26, 2024 | Combs Andrew | Chief Chemistry Officer | Buy | 63,075 | $1.36 | $85.5K | 377,623 |
| Dec 20, 2024 | Lim Bryant David | CLO, Interim CFO, Corp Sec. | Buy | 25,000 | $0.91 | $22.6K | 27,400New Position |
| Dec 20, 2024 | Vaddi Krishna | CEO | Buy | 106,888 | $0.93 | $99.3K | 1,167,275 |
| May 26, 2023 | Vaddi Krishna | CEO | Buy | 1,900 | $5.15 | $9.8K | 1,067,275 |
| May 25, 2023 | Chardonnet Laurent | Chief Financial Officer | Buy | 5,000 | $5.50 | $27.5K | 42,165 |
| May 25, 2023 | Lim Bryant David | Chief Legal Officer, Corp Sec. | Buy | 2,400 | $5.39 | $12.9K | 2,400 |
| May 25, 2023 | Vaddi Krishna | CEO | Buy | 11,856 | $5.63 | $66.7K | 1,065,375 |
| May 24, 2023 | ORBIMED ADVISORS LLC | Director | Buy | 869,565 | $5.75 | $5.00M1.1% OS | 10,119,756 |
| Apr 6, 2023 | Huang Jane | President, CMO | Sell | 13,280 | $6.12 | $81.3K | 24,220-35% |
| Dec 21, 2022 | Vaddi Krishna | CEO | Buy | 19,188 | $5.13 | $98.4K | 120,665 |
| Dec 12, 2022 | Chardonnet Laurent | Chief Financial Officer | Buy | 10,000 | $4.76 | $47.6K | 35,873+39% |
| Jun 1, 2022 | Chardonnet Laurent | Chief Financial Officer | Buy | 10,000 | $4.23 | $42.3K | 24,500+69% |
| Dec 17, 2021 | Morosini Deborah | EVP, Chief of Clinical Affairs | Sell | 28,751 | $13.00 | $373.8K | 444-98% |
| Dec 15, 2021 | Combs Andrew | EVP, Head of Chemistry | Buy | 8,000 | $11.86 | $94.9K | 268,380 |
| Nov 18, 2021 | Morosini Deborah | EVP, Chief of Clinical Affairs | Sell | 28,751 | $15.88 | $456.5K | 844-97% |
| Oct 6, 2021 | Mauro David J | Chief Medical Officer | Sell | 15,000 | $30.96 | $464.4K | 9,092-62% |
| Sep 9, 2021 | Mauro David J | Chief Medical Officer | Sell | 15,000 | $36.69 | $550.3K | 7,513-67% |
| Sep 7, 2021 | Pierce Christopher | EVP and Chief of Business Oper | Sell | 17,000 | $41.68 | $708.5K | 17,407-49% |
| Aug 30, 2021 | Scherle Peggy | Chief Scientific Officer | Sell | 7,714 | $35.75 | $275.8K | 176,234 |
| Aug 27, 2021 | Piper Brian | Chief Financial Officer | Sell | 8,333 | $33.34 | $277.8K | 6,233-57% |
| Aug 17, 2021 | Scherle Peggy | Chief Scientific Officer | Sell | 2,286 | $35.07 | $80.2K | 172,920 |
| Aug 9, 2021 | Mauro David J | Chief Medical Officer | Sell | 15,000 | $31.09 | $466.4K | 8,884-63% |
| Jul 29, 2021 | Scherle Peggy | Chief Scientific Officer | Sell | 20,000 | $35.47 | $709.4K | 173,600 |
| Jul 8, 2021 | Mauro David J | Chief Medical Officer | Sell | 15,000 | $27.47 | $412.1K | 4,555-77% |
| Jun 9, 2021 | Mauro David J | Chief Medical Officer | Sell | 15,000 | $32.44 | $486.6K | 13,600-52% |
| May 27, 2021 | Piper Brian | Chief Financial Officer | Sell | 8,333 | $34.27 | $285.5K | 5,223-61% |
| May 11, 2021 | Scherle Peggy | Chief Scientific Officer | Sell | 10,000 | $40.82 | $408.2K | 178,956 |
| May 10, 2021 | Mauro David J | Chief Medical Officer | Sell | 15,000 | $40.14 | $602.1K | 11,585-56% |
| Apr 30, 2021 | Morosini Deborah | EVP, Chief of Clinical Affairs | Sell | 3,223 | $40.29 | $129.9K | 444-88% |
| Apr 30, 2021 | Pierce Christopher | EVP and Chief of Business Oper | Sell | 3,295 | $40.29 | $132.8K | 3,750-47% |
| Apr 29, 2021 | Mauro David J | Chief Medical Officer | Sell | 25,000 | $35.39 | $884.8K | 17,312-59% |
| Apr 21, 2021 | Mauro David J | Chief Medical Officer | Sell | 25,000 | $30.89 | $772.3K | 4,000-86% |
| Apr 15, 2021 | Mauro David J | Chief Medical Officer | Sell | 9,617 | $38.35 | $368.9K | 6,343-60% |
| Apr 15, 2021 | Morosini Deborah | EVP, Chief of Clinical Affairs | Sell | 100 | $40.00 | $4.0K | 444 |
| Apr 15, 2021 | Pierce Christopher | EVP and Chief of Business Oper | Sell | 200 | $40.00 | $8.0K | 3,750 |
| Apr 15, 2021 | Scherle Peggy | Chief Scientific Officer | Sell | 4,630 | $38.34 | $177.5K | 176,133 |
| Apr 9, 2021 | Mauro David J | Chief Medical Officer | Sell | 15,383 | $39.33 | $605.0K | 7,083-68% |
Showing 1–50 of 53
1 / 2
PRLD Insider Buying Activity
The following table shows recent insider purchases of Prelude Therapeutics Incorporated (PRLD) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 23, 2026 | Bonita David P | director, 10 percent owner: | Buy | 2,815,315 | $4.44 | $12.50M3.7% OS | 11,808,945+31% |
| Apr 23, 2026 | ORBIMED ADVISORS LLC | director, 10 percent owner: | Buy | 2,815,315 | $4.44 | $12.50M3.7% OS | 11,808,945+31% |
| Apr 22, 2026 | BAKER BROS. ADVISORS LP | director, 10 percent owner: | Buy | 2,252,252 | $0.00 | $225.232.9% OS | 20,105,994 |
| Mar 25, 2025 | Combs Andrew | Chief Chemistry Officer | Buy | 100,000 | $0.69 | $69.3K | 0 |
| Mar 25, 2025 | Vaddi Krishna | CEO | Buy | 675,000 | $0.69 | $467.4K0.9% OS | 0 |
| Mar 20, 2025 | Vaddi Krishna | CEO | Buy | 20,416 | $0.73 | $14.9K | 0 |
| Mar 14, 2025 | Vaddi Krishna | CEO | Buy | 39,105 | $0.75 | $29.5K | 0 |
| Mar 12, 2025 | Vaddi Krishna | CEO | Buy | 97,500 | $0.71 | $69.6K | 0 |
| Jan 3, 2025 | Vaddi Krishna | CEO | Buy | 5,000 | $1.21 | $6.0K | 142,553 |
| Jan 2, 2025 | Vaddi Krishna | CEO | Buy | 10,000 | $1.20 | $12.0K | 137,553 |
| Dec 26, 2024 | Combs Andrew | Chief Chemistry Officer | Buy | 63,075 | $1.36 | $85.5K | 377,623 |
| Dec 20, 2024 | Lim Bryant David | CLO, Interim CFO, Corp Sec. | Buy | 25,000 | $0.91 | $22.6K | 27,400New Position |
| Dec 20, 2024 | Vaddi Krishna | CEO | Buy | 106,888 | $0.93 | $99.3K | 1,167,275 |
| May 26, 2023 | Vaddi Krishna | CEO | Buy | 1,900 | $5.15 | $9.8K | 1,067,275 |
| May 25, 2023 | Chardonnet Laurent | Chief Financial Officer | Buy | 5,000 | $5.50 | $27.5K | 42,165 |
| May 25, 2023 | Lim Bryant David | Chief Legal Officer, Corp Sec. | Buy | 2,400 | $5.39 | $12.9K | 2,400 |
| May 25, 2023 | Vaddi Krishna | CEO | Buy | 11,856 | $5.63 | $66.7K | 1,065,375 |
| May 24, 2023 | ORBIMED ADVISORS LLC | Director | Buy | 869,565 | $5.75 | $5.00M1.1% OS | 10,119,756 |
| Dec 21, 2022 | Vaddi Krishna | CEO | Buy | 19,188 | $5.13 | $98.4K | 120,665 |
| Dec 12, 2022 | Chardonnet Laurent | Chief Financial Officer | Buy | 10,000 | $4.76 | $47.6K | 35,873+39% |
| Jun 1, 2022 | Chardonnet Laurent | Chief Financial Officer | Buy | 10,000 | $4.23 | $42.3K | 24,500+69% |
| Dec 15, 2021 | Combs Andrew | EVP, Head of Chemistry | Buy | 8,000 | $11.86 | $94.9K | 268,380 |
PRLD Insider Selling Activity
The following table shows recent insider sales of Prelude Therapeutics Incorporated (PRLD) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Oct 4, 2025 | Huang Jane | President, CMO | Sell | 3,355 | $1.47 | $4.9K | 0 |
| Jul 4, 2025 | Huang Jane | President, CMO | Sell | 3,355 | $0.79 | $2.7K | 0 |
| Apr 4, 2025 | Huang Jane | President, CMO | Sell | 3,355 | $0.68 | $2.3K | 0 |
| Apr 6, 2023 | Huang Jane | President, CMO | Sell | 13,280 | $6.12 | $81.3K | 24,220-35% |
| Dec 17, 2021 | Morosini Deborah | EVP, Chief of Clinical Affairs | Sell | 28,751 | $13.00 | $373.8K | 444-98% |
| Nov 18, 2021 | Morosini Deborah | EVP, Chief of Clinical Affairs | Sell | 28,751 | $15.88 | $456.5K | 844-97% |
| Oct 6, 2021 | Mauro David J | Chief Medical Officer | Sell | 15,000 | $30.96 | $464.4K | 9,092-62% |
| Sep 9, 2021 | Mauro David J | Chief Medical Officer | Sell | 15,000 | $36.69 | $550.3K | 7,513-67% |
| Sep 7, 2021 | Pierce Christopher | EVP and Chief of Business Oper | Sell | 17,000 | $41.68 | $708.5K | 17,407-49% |
| Aug 30, 2021 | Scherle Peggy | Chief Scientific Officer | Sell | 7,714 | $35.75 | $275.8K | 176,234 |
| Aug 27, 2021 | Piper Brian | Chief Financial Officer | Sell | 8,333 | $33.34 | $277.8K | 6,233-57% |
| Aug 17, 2021 | Scherle Peggy | Chief Scientific Officer | Sell | 2,286 | $35.07 | $80.2K | 172,920 |
| Aug 9, 2021 | Mauro David J | Chief Medical Officer | Sell | 15,000 | $31.09 | $466.4K | 8,884-63% |
| Jul 29, 2021 | Scherle Peggy | Chief Scientific Officer | Sell | 20,000 | $35.47 | $709.4K | 173,600 |
| Jul 8, 2021 | Mauro David J | Chief Medical Officer | Sell | 15,000 | $27.47 | $412.1K | 4,555-77% |
| Jun 9, 2021 | Mauro David J | Chief Medical Officer | Sell | 15,000 | $32.44 | $486.6K | 13,600-52% |
| May 27, 2021 | Piper Brian | Chief Financial Officer | Sell | 8,333 | $34.27 | $285.5K | 5,223-61% |
| May 11, 2021 | Scherle Peggy | Chief Scientific Officer | Sell | 10,000 | $40.82 | $408.2K | 178,956 |
| May 10, 2021 | Mauro David J | Chief Medical Officer | Sell | 15,000 | $40.14 | $602.1K | 11,585-56% |
| Apr 30, 2021 | Morosini Deborah | EVP, Chief of Clinical Affairs | Sell | 3,223 | $40.29 | $129.9K | 444-88% |
| Apr 30, 2021 | Pierce Christopher | EVP and Chief of Business Oper | Sell | 3,295 | $40.29 | $132.8K | 3,750-47% |
| Apr 29, 2021 | Mauro David J | Chief Medical Officer | Sell | 25,000 | $35.39 | $884.8K | 17,312-59% |
| Apr 21, 2021 | Mauro David J | Chief Medical Officer | Sell | 25,000 | $30.89 | $772.3K | 4,000-86% |
| Apr 15, 2021 | Mauro David J | Chief Medical Officer | Sell | 9,617 | $38.35 | $368.9K | 6,343-60% |
| Apr 15, 2021 | Morosini Deborah | EVP, Chief of Clinical Affairs | Sell | 100 | $40.00 | $4.0K | 444 |
| Apr 15, 2021 | Pierce Christopher | EVP and Chief of Business Oper | Sell | 200 | $40.00 | $8.0K | 3,750 |
| Apr 15, 2021 | Scherle Peggy | Chief Scientific Officer | Sell | 4,630 | $38.34 | $177.5K | 176,133 |
| Apr 9, 2021 | Mauro David J | Chief Medical Officer | Sell | 15,383 | $39.33 | $605.0K | 7,083-68% |
PRLD Insiders
Similar Stocks to PRLD
VRTX
Vertex Pharmaceuticals Incorporated
$429.19+0.77%
$111.71B
REGN
Regeneron Pharmaceuticals, Inc.
$740.38-0.55%
$77.87B
ALNY
Alnylam Pharmaceuticals, Inc.
$305.79-0.88%
$41.24B
INSM
Insmed Incorporated
$133.47-1.85%
$30.79B
RVMD
Revolution Medicines, Inc.
$146.58+11.18%
$29.51B
UTHR
United Therapeutics Corporation
$566.52-0.06%
$25.13B
MRNA
Moderna, Inc.
$46.88-3.78%
$21.42B
RPRX
Royalty Pharma plc
$49.86+0.42%
$21.20B